Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Johnson and Johnson
US Department of Justice
Boehringer Ingelheim

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,147,095

« Back to Dashboard

Which drugs does patent 6,147,095 protect, and when does it expire?

Patent 6,147,095 protects APTIVUS and is included in two NDAs.

Protection for APTIVUS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 6,147,095

Title: Method for improving the pharmacokinetics of tipranavir
Abstract:The present invention relates to a novel method for improving the pharmacokinetics of tipranavir, comprising administering to a human in need of such treatment a combination of a therapeutically effective amount of tipranavir or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of ritonavir or a pharmaceutically acceptable salt thereof.
Inventor(s): Ferry; James J. (Kalamazoo, MI), Baldwin; John R. (Portage, MI), Borin; Marie T. (Kalamazoo, MI)
Assignee: Pharmacia & Upjohn Company (Kalamazoo, MI)
Application Number:09/430,742
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Boehringer IngelheimAPTIVUStipranavirCAPSULE;ORAL021814-001Jun 22, 2005RXYesYes► Subscribe► Subscribe► SubscribeY
Boehringer IngelheimAPTIVUStipranavirSOLUTION;ORAL022292-001Jun 23, 2008RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,147,095

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan580387► Subscribe
Peru12962000► Subscribe
Malaysia118526► Subscribe
Japan2002528502► Subscribe
Hong Kong1040625► Subscribe
European Patent Office1712231► Subscribe
European Patent Office1126847► Subscribe
Colombia5160321► Subscribe
China1154491► Subscribe
China1324237► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Fish and Richardson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: